Elizabeth Olson Hexner, M.D., M.S.T.R.
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania - Rhoads 7 Liquid Tumor Service
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215.614.1847
Fax: (215) 615-5888
Fax: (215) 615-5888
Education:
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
Post-Graduate Training
Intern, Department of Medicine, Columbia Presbyterian Hospital, 1999-2000.
Resident, Department of Medicine, Columbia Presbyterian Hospital, 2000-2002.
Fellow, Hematology/Oncology, University of Pennsylvania, 2002-2005.
Intern, Department of Medicine, Columbia Presbyterian Hospital, 1999-2000.
Resident, Department of Medicine, Columbia Presbyterian Hospital, 2000-2002.
Fellow, Hematology/Oncology, University of Pennsylvania, 2002-2005.
Certifications
American Board of Internal Medicine (Internal Medicine), 2002.
American Board of Internal Medicine (Medical Oncology), 2005.
American Board of Internal Medicine (Hematology), 2005.
Permanent linkAmerican Board of Internal Medicine (Internal Medicine), 2002.
American Board of Internal Medicine (Medical Oncology), 2005.
American Board of Internal Medicine (Hematology), 2005.
Description of Research Expertise
Myeloproliferative DisordersUmbilical Cord Blood Transplantation
Description of Clinical Expertise
Myeloproliferative NeoplasmsMyelodysplastic Syndromes
Acute leukemia
Selected Publications
Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, Clementi R, Bensen-Kennedy D, and Moliterno A.: Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with the JAK2-V617F mutation. Br J Haematol 164: 83–93, 2014.Hexner, E: Essential Thrombocythemia. Rare Disease Database, National Organization for Rare Diseases (NORD) 2014 Notes: https://www.rarediseases.org/rare-disease-information/rare-diseases/byID/577/viewFullReport.
Babushok, D., Hexner, E.: Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? Curr Opin Hematol 21(2): 114-22, 2014.
Tong, Q., He, S., Xie, F., Mochizuki, K., Liu, Y., Mochizuki, I., Meng, L., Sun, H., Zhang, Y., Guo, Y., Hexner, E., Zhang, Y.: Ezh2 Regulates Transcriptional and Posttranslational Expression of T-bet and Promotes Th1 Cell Responses Mediating Aplastic Anemia in Mice. J Immunol 2014.
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., Dipersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V., Kantarjian, H. M.: Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013.
Mesa, R. A., Kiladjian, J. J., Verstovsek, S., Al-Ali, H. K., Gotlib, J. R., Gisslinger, H., Levy, R. S., Siulnik, A., Gupta, V., Khan, M., Dipersio, J. F., McQuitty, M., Catalano, J. V., Hunter, D. S., Knoops, L., Deininger, M., Cervantes, F., Miller, C., Vannucchi, A. M., Silver, R. T., Barbui, T., Talpaz, M., Barosi, G., Winton, E. F., Mendeson, E., Harvey, J. H., Arcasoy, M. O., Hexner, E., Lyons, R. M., Paquette, R., Raza, A., Sun, W., Sandor, V., Kantarjian, H. M., Harrison, C.: Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 2013.
Landsburg, D. J., Stadtmauer, E., Loren, A., Goldstein, S., Frey, N., Nasta, S. D., Porter, D. L., Tsai, D. E., Perl, A. E., Hexner, E. O., Luger, S.: Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens. Am J Hematol 88(8): 657-60, 2013.
Kumar, A. J., Hexner, E. O., Frey, N. V., Luger, S. M., Loren, A. W., Reshef, R., Boyer, J., Smith, J., Stadtmauer, E. A., Levine, B. L., June, C. H., Porter, D. L., Goldstein, S. C.: Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biol Blood Marrow Transplant 19(7): 1094-101, 2013.
Lin, X., Rice, K. L., Buzzai, M., Hexner, E., Costa, F. F., Kilpivaara, O., Mullally, A., Soares, M. B., Ebert, B. L., Levine, R., Licht, J. D.: miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia 27: 344 - 52, 2013.
Kalota, A., Jeschke, G. R., Carroll, M., Hexner, E. O.: Intrinsic resistance to JAK2 inhibition in myelofibrosis. Clin Cancer Res 2013.
